UCB
Update in progressUCB.VI (Vienna)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
UCB SA is a Brussels-based biopharmaceutical company that develops medicines for neurology and immunology diseases worldwide. Its products include Cimzia for inflammatory conditions; Vimpat, Keppra, Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam for seizure clusters; Zyrtec and Xyzal for allergies; Evenity for postmenopausal osteoporosis; Bimzelx for psoriasis and related conditions; Fintepla for Dravet and Lennox-Gastaut syndromes; RYSTIGGO and ZILBRYSQ for generalized myasthenia gravis. It also provides contract manufacturing.
Company score
- Sentiment
- 2.68
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.34
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 2.67
- Governance
- 0.47
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 1.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.85
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!